Amanda Lowe, DO
Family Medicine · Pikeville, KYNPI 1225357619
Payments from drug & device makers
Across 201 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$604
- AbbVie$503
- Lilly USA, LLC$346
- Bayer$241
- Amgen$235
- AstraZeneca$222
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,151100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $604 |
| AbbVie(2 entities) | 23 | $503 |
| Lilly USA, LLC | 23 | $346 |
| Bayer | 15 | $241 |
| Amgen | 12 | $235 |
| AstraZeneca(2 entities) | 14 | $222 |
| GSK | 13 | $187 |
| Merck | 8 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $90 |
| Daiichi Sankyo Inc. | 6 | $89 |
| Pfizer | 5 | $85 |
| Boehringer Ingelheim | 4 | $68 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| Dexcom, Inc. | 2 | $49 |
| Xeris Pharmaceuticals, Inc. | 3 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Novartis | 2 | $24 |
| Sobi, Inc | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| United Therapeutics Corporation | 1 | $19 |
| Abbott | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Smith+Nephew | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$3,162 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $147,053 |
| FarxigaDapagliflozin Propanediol | 142 | $136,974 |
| MounjaroTirzepatide | 101 | $127,456 |
| JardianceEmpagliflozin | 72 | $87,171 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $86,779 |
| TradjentaLinagliptin | 63 | $57,356 |
| JanuviaSitagliptin Phosphate | 52 | $56,669 |
| KerendiaFinerenone | 63 | $56,016 |
| XareltoRivaroxaban | 29 | $42,780 |
| TrulicityDulaglutide | 28 | $34,290 |
| EliquisApixaban | 28 | $21,288 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $19,248 |
| Victoza 3-PakLiraglutide | 12 | $19,087 |
| LinzessLinaclotide | 16 | $18,271 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 110 | $16,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Byetta, Brilinta | $222 | $175,064192 claims |
| Lilly USA, LLCMounjaro, Trulicity | $346 | $161,746129 claims |
| Novo NordiskOzempic | $604 | $147,053120 claims |
| Boehringer IngelheimJardiance, Tradjenta | $68 | $144,526135 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $187 | $97,32593 claims |
| MerckJanuvia | $116 | $56,66952 claims |
| BayerKerendia | $241 | $56,01663 claims |
| Johnson & JohnsonXarelto | $12 | $42,78029 claims |
| PfizerEliquis | $85 | $21,28828 claims |
| AbbVieLinzess | $503 | $18,27116 claims |
| NovartisEntresto | $24 | $2,59312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Pikeville
- Suzanne FordPikeville$19K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.